EGFR and cancer: Osimertinib was the first FDA and EMA-approved third-generation EGFR-TKI which received marketing authorization in the first-line for patients with advanced tumors harboring activating EGFR mutations and for patients whose cancer cells show T790M mutations after prior EGFR-TKI treatments [3,9].